Medical Education Grants

• Educate on the burden of nighttime and daytime symptoms associated with narcolepsy
• Educate on the impact of treatments on disrupted nighttime sleep and daytime symptoms in narcolepsy patients
• Educate on the burden of illness, including the increased risk and burden of cardiovascular, cardiometabolic, and renal comorbidities
• Educate on the potential impact of excessive sodium intake on near- and long-term health and the relevant risk in narcolepsy patients
• ​Educate on treatment options (individualized dosing, titration, treatment transition) for narcolepsy including treatment paradigms for lifelong illness related to cardiovascular, cardiometabolic and renal comorbidities
• Educate on the importance of diagnosing narcolepsy in underserved care settings and vulnerable populations

• Burden of symptoms associated with Idiopathic Hypersomnia (e.g., ineffective nighttime sleep, sleep inertia, EDS, prolonged sleep duration) and the impact of treatment, including efficacy on nighttime and daytime symptoms, safety, quality of life considerations, and individualized dosing
• The clinical comorbidity burden of Idiopathic Hypersomnia, including cardiovascular/cardiometabolic and renal comorbidities, and impact of treatment choices
• The potential impact of excessive sodium intake on health and relevance of this risk in Idiopathic Hypersomnia patients
• Screening, differential diagnosis, and management of Idiopathic Hypersomnia

• Enhance recognition and diagnosis of LGS in adults, with a focus on understanding its diverse causes and the role of genetic testing.
• Support identification of patients with treatment-resistant epilepsy (TRE) who may have LGS, through comprehensive clinical assessment and use of screening tools.
• Promote holistic care approaches for TREs and DEEs, addressing seizures as well as cognitive, behavioral, and neuropsychiatric symptoms through multidisciplinary strategies.
• Encourage integration non-seizure outcomes in care of patients with epilepsy—such as cognition, behavior, sleep, and quality of life—into personalized treatment plans using appropriate assessment tools.
• Provide guidance on optimizing newer and novel anti-seizure therapies, including dosing, drug interactions, and strategies to reduce medication burden and improve treatment outcomes.
• Empower HCPs, patients, and caregivers to improve therapy adherence and access, including navigating payer processes, leveraging support programs, and ensuring equitable care for underserved populations.

1. Holistic Symptom Management in DEEs and Epilepsy
   • Increase awareness and clinical understanding of non-seizure symptoms, including behavioral disturbances, sleep disturbances, and mood-related challenges, patient-reported outcomes (PROs) and their impact on quality of life.
   • Increase awareness, understanding and management of TAND symptoms in TSC patients, including the use of screening tools TAND-L and TAND-SQ.
   • Promote integration of multidimensional symptom tracking into routine care.
   • Rational reduction in medication burden
2. Chronic and Long-Term Care Strategies for DEEs
   • Educate on comprehensive management of diverse DEE populations.
   • Address real-world care models in long-term care settings, including multidisciplinary care coordination.
   • Support clinicians in navigating complex care pathways for chronic DEE patients.
3. Safe and Effective Therapeutic Optimization
   • ​Provide guidance on polypharmacy and drug cycling management, including drug-drug interactions, side effect mitigation strategies, and rational therapeutic decision-making and a rational reduction in medication burden.
   • Encourage evidence-based approaches to treatment expansion and optimization, while remaining agnostic to specific products.

• Education on the complexity of cannabinoid science to better understand the importance of high-quality evidence to assess cannabinoid-based drugs.
• Evaluation of differences in evidence/data presented for cannabinoid-based drug products submitted for regulatory approval (including, for example FDA, EMA, MHRA, PMDA).
• Assessments of the risk profiles for under-regulated cannabinoid products.

Support educational initiatives regarding:

1. Role of ASP in the management of pediatric, adolescent/young adult (AYA) and adult ALL/LBL
2. Differentiating unique ASP profiles including unique mechanisms, efficacy, and safety in combination with current and emerging treatments
3. Clinical application of pediatric inspired regimens in the AYA population
4. The efficacy and clinical benefits of short-acting ASP formulations in ALL/LBL, including applicability to special populations (eg, obese, elderly)
5. Evidence-based patient management strategies to address AEs specific to ASP
6. Team -based education to support multidisciplinary implementation across age groups and care environments with a focus on regional/community practice settings
7. Patient and caregiver education to support QoL
8. Evidence-based managed care considerations for ALL management

Support educational initiatives that:

1. Advance timely diagnosis and treatment initiation for high-risk AML, including secondary AML subgroups
2. Optimize evidence-based treatment strategies for effective treatment planning and clinical management of high-risk AML
3. Improve supportive care and patient management in diverse care settings
4. Explore innovative approaches and technologies for AML treatment delivery

1. The rationale for targeting HER2 over-expression in GI cancers
2. Guideline-concordant HER2 testing and evidence-based scoring best practices in GI cancers
3. Patient selection and individualized treatment approaches for patients with HER2-positive GI cancers based on clinical guidelines and peer-reviewed publications
4. Current and emerging therapies for HER2-positive GI cancers including:
   • Mechanism of Action
   • Efficacy
   • Safety
5. Treatment selection considerations for HER2-targeting therapies in BTC and GEA
6. Evidence-based patient management strategies to address AEs specific to HER2-targeting therapies
7. Evidence-based managed care considerations for therapies targeting HER2 in BTC and GEA

Support educational initiatives regarding

1. Foundational science & disease understanding: The biology and clinical significance of H3 K27M-mutant gliomas across age groups.
2. Diagnosis & testing: Awareness of best practices in imaging, biopsy, and molecular diagnostics to support accurate and timely diagnosis.
3. Therapeutic advances: Knowledge of current and emerging treatment options, including those under clinical investigation.
4. Clinical decision-making: Guidance on treatment planning and decision making, including management approaches in the disease progression setting.
5. Monitoring response and progression assessment: Improve understanding of RANO 2.0 criteria and how to translate it into real world decision-making.
6. Collaborative care models: Multidisciplinary approaches to optimize patient outcomes and care coordination.

Support educational initiatives regarding:

1. First- and second-line treatment options and therapy sequencing in SCLC management
2. Current considerations in first-line maintenance and second-line SCLC therapies including:
   1. Mechanism of action
   2. Efficacy
   3. Safety
   4. Evidence-based best practices
3. Best practices for patient management in first and later lines of SCLC treatment
4. Evidence-based managed care considerations for SCLC management (1L and subsequent therapies)